Flex Databases: Ania Neyroset

2019: Use of AI in a system on pharmacovigilance

On April 16, 2019 the St. Petersburg IT company Flex Databases announced use of artificial intelligence in a system on pharmacovigilance.

According to determination of WHO, "The pharmacovigilance is the scientific research and types of activity connected with identification, assessment, understanding and prevention of the ghost effects or any other problems connected with medicine"^[1].

The self-training neuronet which developers named Ania looks for signals on security of medicines on the basis of an array of messages about undesirable reactions, is engaged in automatic coding of medical terms according to the MedDRA dictionary and detection of duplicates of messages about undesirable reactions. Ania is capable to process artificial intelligence in 30 seconds prior to hundred thousand messages about undesirable reactions.

Development of a neuronet and also its implementation in pharmacovigilance, was caused by desire more carefully and effectively to process the data which came to a system. The trained neuronet quickly processes large volumes of information and on the put difficult algorithms finds signals where the person can pass them, it in details checks and analyzes data fits and causes and effect relationships. Olga Loginovskaya, director of quality and corporate development of Flex Databases

The term "signal" in pharmacovigilance is understood as the message from one or several sources, authentically confirmatory existence of cause and effect relationship between drug intake and undesirable reaction of which earlier either nothing was known, or data were insufficiently informative.

In spite of the fact that to assessment of a ratio of advantage and risk of medicines it is paid much attention during clinical trials of medicine, the world practice shows that by the time of registration of medicine only a half of ghost effects inherent in it comes to light, and that is about the most frequent (from 1 to 10%), or allergic reactions. The pharmacovigilance collects data and controls security of drugs including during the post-registration period, and gives more complete and exact information about the risks connected with medicine sale. Detection of a large number of signals can affect a ratio "advantage risk" up to that the regulator or pharmaceutical company will make the decision on a medicine output from the market.

The Flex Databases company was included by the international organization of MSSO in the official listing of the vendors supporting MedDRA coding and SMQ requests.

Notes